Internal Medicine, Hematology & Oncology · Tampa, FL
NPI
1952729741
Since 2014
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
3
Medicare group memberships
Hospitals
2
Hospital affiliations
Tampa General Hospital Cancer Instititute, 3 Tampa General Cir,
Tampa, FL, 33606
Phone (813) 844-7585
Groups this clinician bills Medicare through
Medicare paid, 2024
$77K
5,300 services
Medicare patients, 2024
113
Average age 74
Drug cost, 2024
$4.9M
619 prescriptions
Company payments, 2025
$45K
From 19 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by David Swoboda was code 99233 (hospital e&m - subsequent), 83 times for 27 patients. In total David Swoboda billed 5,300 services in 27 codes, and Medicare paid $77K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2022-08-24.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99233 Hospital E&M - Subsequent | Facility | 83 | 27 | $92.11 | $7,645 |
| 99214 Office E&M - Established | Office | 80 | 39 | $89.00 | $7,120 |
| 99214 Office E&M - Established | Facility | 79 | 40 | $69.99 | $5,529 |
| 99215 Office E&M - Established | Facility | 68 | 27 | $105.75 | $7,191 |
| 99232 Hospital E&M - Subsequent | Facility | 55 | 25 | $61.16 | $3,364 |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Facility | 25 | 18 | $12.81 | $320 |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 20 | 17 | $12.81 | $256 |
| 99215 Office E&M - Established | Office | 19 | 17 | $140.13 | $2,662 |
| 99205 Office E&M - New | Facility | 19 | 19 | $127.25 | $2,418 |
| 99205 Office E&M - New | Office | 16 | 16 | $172.24 | $2,756 |
| 99223 Hospital E&M - Initial | Facility | 14 | 11 | $134.36 | $1,881 |
By year: 2022 $66K for 2,720 services; 2023 $138K for 6,001 services; 2024 $77K for 5,300 services.
Lab tests billed to Medicare, 2023
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 85025 Blood Count | 19 | 13 | $7.61 | $145 |
Medicare prescription drug claims, 2024
In 2024, the drug David Swoboda prescribed most often to Medicare patients was Venclexta (Venetoclax), with 97 prescriptions and refills. In total David Swoboda wrote 619 Medicare prescriptions that cost $4.9M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Venclexta Venetoclax | 97 | 97 | 40 | $376K |
| Xospata Gilteritinib Fumarate | 28 | 28 | Under 11 | $596K |
| Acyclovir Generic | 26 | 26 | 11 | $204 |
| Hydroxyurea Generic | 25 | 39 | Under 11 | $530 |
| Idhifa Enasidenib Mesylate | 21 | 21 | Under 11 | $674K |
| Sulfamethoxazole-Trimethoprim Sulfamethoxazole/Trimethoprim | 19 | 26 | Under 11 | $68.54 |
| Cresemba Isavuconazonium Sulfate | 19 | 19 | Under 11 | $110K |
| Scemblix Asciminib Hydrochloride | 18 | 18 | Under 11 | $376K |
| Vanflyta Quizartinib Dihydrochloride | 17 | 17 | Under 11 | $231K |
| Prednisone Generic | 17 | 18 | Under 11 | $65.98 |
| Levofloxacin Generic | 16 | 16 | Under 11 | $154 |
| Jakafi Ruxolitinib Phosphate | 15 | 15 | Under 11 | $244K |
| Iclusig Ponatinib Hcl | 15 | 15 | Under 11 | $302K |
| Ojjaara Momelotinib Dihydrochloride | 14 | 14 | Under 11 | $366K |
| Prochlorperazine Maleate Generic | 14 | 14 | Under 11 | $177 |
Brand drugs: 337 claims; generic drugs: 282 claims; opioid claims: 18.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid David Swoboda $45K ($45K in general payments such as food, travel and fees) from 19 companies. The largest payer was Servier Pharmaceuticals LLC with $16K.
| Company | Payments | Amount |
|---|---|---|
| Servier Pharmaceuticals LLC | 22 | $16K |
| E.R. Squibb & Sons, L.L.C. BMY | 6 | $11K |
| Syndax Pharmaceuticals, Inc. SNDX | 5 | $6,892 |
| GlaxoSmithKline, LLC. GSK | 6 | $5,099 |
| Daiichi Sankyo Inc. 4568.T | 6 | $3,040 |
| Geron Corporation GERN | 7 | $2,528 |
| Genzyme Corporation SNY | 2 | $211 |
| Celgene Corporation BMY | 2 | $173 |
| AstraZeneca Pharmaceuticals LP AZN | 1 | $68.49 |
| Amgen Inc. AMGN | 1 | $53.68 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.